- Home
- MED vs MDWD Comparison
MED vs MDWD Comparison
Compare MED & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MED
- MDWD
- Stock Information
- Founded
- MED 1980
- MDWD 2000
- Country
- MED United States
- MDWD Israel
- Employees
- MED N/A
- MDWD N/A
- Industry
- MED Packaged Foods
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- MED Consumer Staples
- MDWD Health Care
- Exchange
- MED Nasdaq
- MDWD Nasdaq
- Market Cap
- MED 187.3M
- MDWD 184.8M
- IPO Year
- MED N/A
- MDWD 2014
- Fundamental
- Price
- MED $15.45
- MDWD $18.14
- Analyst Decision
- MED Hold
- MDWD Strong Buy
- Analyst Count
- MED 1
- MDWD 1
- Target Price
- MED $17.00
- MDWD $25.00
- AVG Volume (30 Days)
- MED 244.2K
- MDWD 59.3K
- Earning Date
- MED 02-18-2025
- MDWD 11-26-2024
- Dividend Yield
- MED N/A
- MDWD N/A
- EPS Growth
- MED N/A
- MDWD N/A
- EPS
- MED 0.67
- MDWD N/A
- Revenue
- MED $674,475,000.00
- MDWD $19,720,000.00
- Revenue This Year
- MED N/A
- MDWD $10.37
- Revenue Next Year
- MED N/A
- MDWD $26.36
- P/E Ratio
- MED $23.73
- MDWD N/A
- Revenue Growth
- MED N/A
- MDWD N/A
- 52 Week Low
- MED $15.13
- MDWD $11.04
- 52 Week High
- MED $62.59
- MDWD $24.00
- Technical
- Relative Strength Index (RSI)
- MED 33.14
- MDWD 53.09
- Support Level
- MED $15.10
- MDWD $15.80
- Resistance Level
- MED $17.82
- MDWD $18.25
- Average True Range (ATR)
- MED 0.88
- MDWD 0.81
- MACD
- MED -0.19
- MDWD -0.07
- Stochastic Oscillator
- MED 17.77
- MDWD 77.55
About MED MEDIFAST INC
Medifast Inc is a United states based company that produces, distributes and sells products concerning weight loss, weight management, and healthy living. The company generates its revenue from point of sale transactions executed over an e-commerce platform for weight loss, weight management, and other consumable health and nutritional products.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.